Basit öğe kaydını göster

dc.contributor.authorTotan, Yüksel
dc.contributor.authorGüler, Emre
dc.contributor.authorYüce, Aslıhan
dc.contributor.authorDervişoğulları, Mehmet Serdar
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:56:23Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:56:23Z
dc.date.issued2017en_US
dc.identifier.citationTotan, Y., Güler, E., Yüce, A. ve Dervişoğulları, M. S. (2017). The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa. Indian Journal of Ophthalmology, 65(10), 984-988. https://dx.doi.org/10.4103/ijo.IJO_978_16en_US
dc.identifier.issn0301-4738
dc.identifier.issn1998-3689
dc.identifier.urihttps://dx.doi.org/10.4103/ijo.IJO_978_16
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2689
dc.descriptionWOS: 000413741300015en_US
dc.descriptionPubMed ID: 29044065en_US
dc.description.abstractPurpose: To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP). Methods: A total of 48 eyes of 24 patients (13 males, 11 females) with RP prescribed VPA were included. The length of VPA treatment was 6-12 months (mean 9.4 months). Parameters evaluated were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution [logMAR]), visual field analyses (VFAs) with Humprey automated perimetry, multifocal electroretinography (ERG) with Roland-RETI scan, and VPA side effects. Results: Mean age was 34.3 +/- 10.3 years (range 18-56 years). Fifteen of the patients (30 eyes) had two ERG and VFA tracings, allowing comparison between baseline and follow-up (range 6-12 months). Mean BCVA before and after VPA therapy was 0.36 +/- 0.38 and 0.36 +/- 0.37 logMAR, respectively (P = 0.32). Quantitative perimetric indices including mean deviation and pattern standard deviation were not significantly changed after VPA therapy (P > 0.05). P1 amplitudes (in terms of nV/deg(2) and mV) of ERG waves were significantly decreased in the rings 1, 3, and 4 after VPA therapy (P < 0.05). Regarding the N1 amplitudes, the only significant decrease was observed in area 1 (P = 0.03). In addition, N1 latency was significantly increased in area 3 after VPA therapy (P = 0.04). Conclusions: VPA therapy did not have any significant benefit on BCVA and VFA. In addition, it may be associated with decline in some ERG parameters. Therefore, physicians should avoid prescribing VPA for RP until its safety and efficacy are appropriately evaluated.en_US
dc.language.isoengen_US
dc.publisherMedknow Publications & Media Pvt Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/*
dc.subjectElectroretinogramen_US
dc.subjectRetinitis Pigmentosaen_US
dc.subjectValproic Aciden_US
dc.subjectVisual Fielden_US
dc.titleThe adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosaen_US
dc.typearticleen_US
dc.relation.ispartofIndian Journal of Ophthalmologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume65en_US
dc.identifier.issue10en_US
dc.identifier.startpage984en_US
dc.identifier.endpage988en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.4103/ijo.IJO_978_16en_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess